2 recruiting, 1 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow HS235: new trials by email Literature Review of HS235 trials Research Report on HS235
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction HS235, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 1 / Phase 2 | Recruiting | 35Pharma Inc., a GSK company | 126 | 2026-10-21 | 2026-10-30 |
| A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults HS235, Placebo - Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Recruiting | 35Pharma Inc., a GSK company | 90 | 2026-08-19 | 2026-10-30 |
| Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects HS235, Placebo - Overweight and Obesity | Phase 1 | Completed | 35Pharma Inc | 39 | 2024-11-28 | 2025-12-30 |
Hypertension, Pulmonary (1) · Obesity (1) · Overweight (1) · Pulmonary Arterial Hypertension (1)
35Pharma Inc., a GSK company (2) · 35Pharma Inc (1)
United States (2) · Canada (1) · Spain (1) · United Kingdom (1)